Vrije Universiteit Brussel

 

Publications of HEIM

    2017

  • Tumour-associated macrophage-mediated survival of myeloma cells through STAT3 activation.
    De Beule N, De Veirman K, Maes K, De Bruyne E, Menu E, Breckpot K, De Raeve H, Van Rampelbergh R, Van Ginderachter JA, Schots R, Van Valckenborgh E, Vanderkerken K..
    J Pathol. 2017

  • 2016

  • The myeloma stem cell concept, revisited: from phenomenology to operational terms.
    Johnsen HE, Bøgsted M, Schmitz A, Bødker JS, El-Galaly TC, Johansen P, Valent P, Zojer N, Van Valckenborgh E, Vanderkerken K, van Duin M, Sonneveld P, Perez-Andres M, Orfao A, Dybkær K.
    Haematologica 2016
    241(4):534-546.

  • Extracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myeloma.
    Wang J, Faict S, Maes K, De Bruyne E, Van Valckenborgh E, Schots R, Vanderkerken K, Menu E.
    Oncotarget 2016
    241(4):534-546.

  • A GRP78-Directed Monoclonal Antibody Recaptures Response in Refractory Multiple Myeloma with Extramedullary Involvement.
    Rasche L, Menoret E, Dubljevic V, Menu E, Vanderkerken K, Lapa C, Steinbrunn T, Chatterjee M, Knop S, Düll J, Greenwood DL, Hensel F, Rosenwald A, Einsele H, Brändlein S..
    Clin Cancer Res 2016
    241(4):534-546.

  • Induction of miR-146a by multiple myeloma cells in mesenchymal stromal cells stimulates their pro-tumoral activity.
    De Veirman K, Wang J, Xu S, Leleu X, Himpe E, Maes K, De Bruyne E, Van Valckenborgh E, Vanderkerken K, Menu E, Van Riet I. .
    Cancer Letters 2016
    377(1):17-24

  • SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma
    Heusschen R, Muller J, Binsfeld M, Marty C, Plougonven E, Dubois S, Mahli N, Moermans K, Carmeliet G, Léonard A, Baron F, Beguin Y, Menu E, Cohen-Solal M, Caers J. .
    Oncotarget 2016
    7(21):30712-29

  • Does an NKT-cell-based immunotherapeutic approach have a future in multiple myeloma?
    Favreau M, Vanderkerken K, Elewaut D, Venken K, Menu E. .
    Oncotarget 2016
    7(17):23128-40

  • Abnormal IGF-Binding Protein profile in the bone marrow of multiple myeloma patients.
    Bieghs L, Brohus M, Kristensen I, Abilgaard N, Boegsted M.
    PloS One 2016
    11:e0154256

  • The insulin-like growth factor system in multiple myeloma: diagnostic and therapeutic potential.
    Bieghs L, Hans J, Maes K, Menu E, Van Valckenborgh E, Overgaard MT, Nyegaard M, Conover C, Vanderkerken K, De Bruyne E. .
    Oncotarget 2016
    7(30):48732- 48752

  • Multiple myeloma exosomes establish a favorable bone marrow microenvironment with enhanced angiogenesis and immunosuppression
    Wang J, De Veirman K, Faict S, Frassanito MA, Ribatti D, Vacca A, Menu E.
    J og Pathology 2016
    239(2):162-73

  • Halting pro-survival autophagy by TGFß inhibition in bone marrow fibroblasts overcomes bortezomib resistance in multiple myeloma patients. Leukemia.
    Frassanito A, De Veirman K, Desantis V, Marzo L, Vergara D, Ruggieri S, Annese T, Nico B, Menu E, Catacchio I, Ria R, Racanelli V, Maffia M, Angelucci E, Derudas D, Fumarulo R, Dammacco F, Ribatti D, Vanderkerken K, Vacca A. .
    Leukemia 2016
    30(3):640-648

  • Signal transducer and activator of transcription 3 in myeloid-derived suppressor cells: an opportunity for cancer therapy
    Dufait I, Van Valckenborgh E, Menu E, Escors D, De Ridder M, Breckpot K. .
    Oncotarget 2016

  • Extracellular vesicle cross-talk in the bone marrow microenvironment: implications in multiple myeloma.
    Wang J, Faict S, Maes K, De Bruyne E, Van Valckenborgh E, Schots H, Vanderkerken K. Menu E. .
    Oncotarget 2016
    7(25): 38927-38945

  • Novel strategies to target the ubiquitin proteasome system in multiple myeloma.
    Lub S, Maes K, Menu E, De Bruyne E, Vanderkerken K, Van Valckenborgh E.
    Oncotarget 2016
    7(6):6521-6537

  • Inhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells.
    Lub S, Maes A, Maes K, De Veirman K, De Bruyne E, Menu E, Fostier K, Kassambara A, Moreaux J, Hose D, Leleu X, King RW, Vanderkerken K, Van Valckenborgh E. .
    Oncotarget 2016
    7(4):4062-4076

  • 2015

  • The bone marrow microenvironment enhances multiple myeloma progression by exosome-mediated activation of myeloid-derived suppressor cells.
    Wang J, De Veirman K, De Beule N, Maes K, De Bruyne E, Van Valckenborgh E, Vanderkerken K, Menu E. .
    Oncotarget 2015
    6(41):43992-44004

  • Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche.
    Lawson MA, McDonald MM, Kovacic N, Hua Khoo W, Terry RL, Down J, Kaplan W, Paton-Hough J, Fellows C, Pettitt JA, Neil Dear T, Van Valckenborgh E, Baldock PA, Rogers MJ, Eaton CL, Vanderkerken K, Pettit AR, Quinn JM, Zannettino AC, Phan TG, Croucher PI. .
    Nat.Commun. 2015
    6:8983.

  • Increased resistance to proteasome inhibitors in multiple myeloma mediated by cIAP2 - implications for a combinatorial treatment.
    Duvefelt CF, Lub S, Agarwal P, Arngården L, Hammarberg A, Maes K, Van Valckenborgh E, Vanderkerken K, Jernberg-Wiklund H..
    Oncotarget 2015
    6(24):20621-35

  • Multiple myeloma induces Mcl-1 expression and survival of myeloid-derived suppressor cells.
    De Veirman K, Van Ginderachter JA, Lub S, De Beule N, Thielemans K, Bautmans I, Oyajobi BO, De Bruyne E, Menu E, Lemaire M, Van Riet I, Vanderkerken K, Van Valckenborgh E. .
    Oncotarget 2015
    6(12):10532-47

  • 2014

  • Myeloid-derived suppressor cells as therapeutic target in hematological malignancies.
    De Veirman K, Van Valckenborgh E, Lahmar O, Geeraerts X, De Bruyne E, Menu E, Van Riet I, Vanderkerken K, Van Ginderachter J. .
    Front Oncol. 2014
    4:349.

  • In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated withprognosis and immunomodulation in multiple myeloma
    Maes K, De Smedt E, Kassambara A, Hose d, Seckingera, Van Valckenborgh E, Menu E, Klein B, Vanderkerken K, Moreaux J, De Bruyne E, .
    2014 Oncotarget .

  • Stimulation of invariant natural killer T cells by a-Galactosylceramide activates the JAK-STAT pathway in endothelial cells and reduces angiogenesis in the 5T33 multiple myeloma model.
    Nur H, Rao L, Frassanito MA, De Raeve H, Ribatti D, Mfopou JK, Van Valckenborgh E, De Bruyne E, Vacca A, Vanderkerken K, Menu E. .
    2014 B J Haem doi: 10.1111/bjh.13092 .

  • The IGF-1 receptor inhibitor picropodophyllin potentiates the anti-myeloma activity of a BH3-mimetic.
    Bieghs L, Lub S, Fostier K, Maes K, Van Valckenborgh E, Menu E, Johnsen HE, Overgaard MT, Larsson O, Axelson M, Nyegaard M, Schots R, Jernberg-Wiklund H, Vanderkerken K, De Bruyne E. .
    2014 Oncotarget .

  • Cancer associated fibroblasts and tumor growth: focus on multiple myeloma.
    De Veirman K, Rao L, De Bruyne E, Menu E, Van Valckenborgh E, Van Riet I, Frassanito MA, Di Marzo L, Vacca A, Vanderkerken K. .
    2014 Cancers (Basel) 6(3):1363-81 .

  • Bone marrow stromal cell-derived exosomes as communicators in drug resistance in multiple myeloma cells.
    Wang J, Hendrix A, Hernot S, Lemaire M, De Bruyne E, Van Valckenborgh E, Lahoutte T, De Wever O, Vanderkerken K, Menu E .
    2014 Blood 124(4):555-66 .

  • The role of DNA damage and repair in decitabine-mediated apoptosis in multiple myeloma.
    Maes K, De Smedt E, Lemaire M, De Raeve H, Menu E, Van Valckenborgh E, McClue S, Vanderkerken K, De Bruyne E. .
    2014 Oncotarget 5(10):3115-29 .

  • Imaging and radioimmunotherapy of multiple myeloma with anti-idiotypic Nanobodies.
    Lemaire M, D'Huyvetter M, Lahoutte T, Van Valckenborgh E, Menu E , De Bruyne E, Kronenberger P, Wernery U, Muyldermans S, Devoogdt N, Vanderkerken K. .
    2014 Leukemia 28(2):444-7 .

  • Bone marrow fibroblasts parallel multiple myeloma progression in patients and mice: in vitro and in vivo studies.
    Frassanito MA, Rao L, Moschetta M, Ria R, Di Marzo L, De Luisi A, Racanelli V, Catacchio I, Berardi S, Basile A, Menu E, Ruggieri S, Nico B, Ribatti D, Fumarulo R, Dammacco F, Vanderkerken K, Vacca A. .
    2014 Leukemia 28(4):904-16 .

  • International Myeloma Working Group. IMWG consensus on risk stratification in multiple myeloma.
    Chng WJ, Dispenzieri A, Chim CS, Fonseca R, Goldschmidt H, Lentzsch S, Munshi N, Palumbo A, Miguel JS, Sonneveld P, Cavo M, Usmani S, Durie BG, Avet-Loiseau H .
    2014 Leukemia 28(2):269-77 .

  • Biological and clinical implications of invariant natural killer T cells in multiple myeloma: rising the potential for immunotherapy
    Haneen Nur .
    2014 .

    2013
  • The potential role of the insulin-like growth factor-I pathway in the development of new therapeutic strategies in multiple myeloma
    Miguel Lemaire .
    2013 .

  • The role of invariant natural killer T cells in cancer
    Nur H, Van Valckenborgh E, De Bruyne E, Vanderkerken K, Menu E. .
    International Blood Research & Reviews, 2013; 1(2): 44-71. .

  • Rituximab purging and/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation
    Pettengell R, Schmitz N, Gisselbrecht C, Smith G, Patton WN, Metzner B, Caballero D, Tilly H, Walewski JA, Bence-Bruckler I, To BIK, Geisler CH, Schots R, Kimby E, Taverna CJ, Kozak T, Dreger P, Uddin R, Ruiz De Elvira C, Goldstone AH. .
    J Clin Oncol 2013;31(13):1624-30. .

  • Darbepoetin-alfa and intravenous iron administration after autologous hematopoietic stem cell transplantation: A prospective multicenter randomized trial.
    Beguin Y, Maertens J, De Prijck B, Schots R, Seidel L, Bonnet C, Hafraoui K, Willems E, Vanstraelen G, Servais S, Jaspers A, Fillet G, Baron F. .
    Am J Hematol. 2013; 88(12):990-6. .

  • Effect of the HDAC inhibitor vorinostat on the osteogenic differentiation of mesenchymal stem cells in vitro and bone formation in vivo.
    Xu S, De Veirman K, Evans HR, Santini G, Vande Broek I, Leleu X, De Becker A, Van Camp B, Croucher PI, Vanderkerken K, Van Riet I. .
    Acta Pharmacol Sin. 2013; 34(5): 699-709 .

  • New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the international myeloma working group (IMWG).
    Ocio EM, Richardson PG, Rajkumar SV, Palumbo A, Mateos MV, Orlowski RZ, Kumar SK, Usmani S, Roodman D, Niesvizky R, Einsele H, Anderson KC, Dimopoulos MA, Avet-Loiseau H, Mellqvist UH, Turesson I, Merlini G, Schots R, Mccarthy P, Bergsagel PL, Chim J, Lahuerta JJ, Shah J, Breiman A, Mikhael J, Zweegman S, Lonial S, Comenzo R, Chng WJ, Moreau P, Sonneveld P, Ludwig H, Durie B, San Miguel JF. .
    Leukemia. 2013 Nov 20. doi: 10.1038/leu.2013.350. [Epub ahead of print] .

  • Preclinical evaluation of invariant natural killer T cells in the 5T33 multiple myeloma model
    Nur H, Fostier K, Aspeslagh S, Renmans W, Bertrand E, Leleu X, Favreau M, Breckpot K, Schots R, De Waele M, Van Valckenborgh E, De Bruyne E, Facon T, Elewaut D, Vanderkerken K, Menu E. .
    PLoS ONE 2013; 8(5): e65075. .

  • An intragenic ERG deletion (ERGdel) is a marker of an oncogenic subtype of B-cell precursor acute lymphoblastic leukemia with a favorable outcome despite frequent IKZF1 deletions
    Clappier E, Auclerc M-F, Rapion J, Bakkus M, Caye A, Khemiri A, Giroux C, Hernandez L, Kabongo E, Savola S, Leblanc T, Yakouben K, Plat G, Costa V, Ferster A, Girard S, Fenneteau O, Cayuela J-M, Sigaux F, Dastugue N, Suciu S, Benoit Y, Bertrand Y, Soulier J, Cave H. .
    Leukemia. 2013 Sep 25. doi: 10.1038/leu.2013.277. [Epub ahead of print] .

  • Predictive factors of allosensitization after immunosuppressant withdrawal in recipients of long-term cultured islet cell grafts
    Hilbrands R, Gillard P, Van Der Torren C, Ling Z, Verheyden S, Jacobs-Tulleneers-Thevissen D, Roep B, Claas F, Demanet C, Gorus F, Pipeleers D, Keymeulen B. .
    Transplantation. 2013; 96(2):162-9. .

  • Response: KIR/HLA incompatibility in HIV-1 transmission and importance of the 'missing self' model.
    Jennes W, Verheyden S, Mertens JW, Camara M, Seydi M, Dieye TN, Mboup S, Demanet C, Kestens L. .
    Blood. 2013;122(11):1984-5. .

  • Mithramycin exerts an anti-Myeloma effect and displays anti-angiogenic effects through up-regulation of anti-angiogenic factors
    Otjacques E, Binsfeld M, Rocks N, Blacher S, Vanderkerken K, Noel A, Beguin Y, Cataldo D, Caers J. .
    Plos One, 2013; 8(5): e62818. .

  • Homozygous antithrombin deficiency in adolescents presenting with lower extremity thrombosis and renal complications: two case reports from Turkey.
    Sarper N, Orlando C, Demirsoy UU, Gelen SA, Jochmans K. .
    J Pediatr Hematol Oncol. 2013 Sep 25. [Epub ahead of print] .

  • Vorinostat-induced bone loss might be related to drug toxicity
    Xu S, De Veirman K, Vanderkerken K, Van Riet I. .
    Bone. 2013;57(2):384-385. .

  • Epigenetic modulating agents as a new therapeutic approach in Multiple Myeloma
    Maes K, Menu E, Van Valckenborgh E, Van Riet I, Vanderkerken K, De Bruyne E. .
    Cancers 2013, 5(2): 430-61 .

  • Diagnosis and follow-up of monoclonal gammopathies of undetermined significance; information for referring physicians.
    Caers J, Vekemans M-C, Bries G, Beel C, Delrieu V, Deweweire A, Demuynck H, De Prijck B, De Samblanx H, Kentos A, Meuleman N, Mineur P, Offner F, Vande Broek I, Van Droogenbroeck J, Van De Velde A, Wu Ka L, Delforge M, Schots R, Doyen C. .
    Ann Med. 2013; 45(5-6):413-22. .

  • Bone marrow fibroblasts parallel multiple myeloma progression in patients and mice: in vitro and in vivo studies
    Frassanito MA, Rao L, Moschetta M, Ria R, Di Marzo L, De Luisi A, Racanelli V, Catacchio I, Basile A, Menu E, Ruggieri S, Nico B, Ribatti D, Fumarulo R, Dammacco F, Vanderkerken K, Vacca A. .
    Leukemia. 2013 Sep 2. doi: 10.1038/leu.2013.254. [Epub ahead of print] .

  • A phase IB study on intravenous synthetic mRNA electroporated dendritic cell immunotherapy in pretreated advanced melanoma patients.
    Wilgenhof S, Van Nuffel A, Benteyn D, Corthals J, Aerts C, Heirman C, Van Riet I, Bonehill A, Thielemans K, Neyns B. .
    Ann Oncol. 2013, 24(10):2686-93. .

  • Synergistic induction of apoptosis in multiple myeloma cells by bortezomib and hypoxia-activated prodrug TH-302, in vivo and in vitro.
    Hu J, Van Valckenborgh E, Xu D, Menu E, De Raeve H, De Bruyne E, Xu S, Van Camp B, Handisides DR, Hart C, Vanderkerken K. .
    Mol Cancer Ther 2013; 12(9):1763-73. .

  • Inhibitory KIR/HLA incompatibility between sexual partners confers protection against HIV-1 transmission.
    Jennes W, Verheyden S, Mertens JW, Camara M, Seydi M, Dieye TN, Mboup S, Demanet C, Kestens L. .
    Blood. 2013;121(7):1157-64 .

  • Upregulation of miR-135b is involved in the impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients
    Xu S, Santini G, De Veirman K, Vande Broek I, Leleu X, De Becker A, Van Camp B, Vanderkerken K, Van Riet I. .
    Plos One, 2013; 8(11):e79752 .

  • Symptomatic myelodysplasia with normal blood counts: a diagnostic enigma complicating the management of a patient with severe platelet dysfunction.
    Van Der Meeren S, De Becker A, De Waele M, De Smet D, Jochmans K .
    Leuk Lymphoma. 2013;54(1):192-4. .

  • Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group.
    Fernández de Larrea C, Kyle R, Durie B, Ludwig H, Usmani OS, Vesole DH, San Miguel JF, Sezer O, Sonneveld P, Kumar SK, Mahindra A, Comenzo R, Palumbo A, Mazumber A, Anderson KC, Richardson PG, Badros AZ, Caers J, Cavo M, Leleu X, Dimopoulos MA, Chim CS, International Myeloma Working Group: Schots R, et al. .
    Leukemia. 2013; 27(4):780-91. .

  • Phagocytic blasts in B-lineage acute lymphoblastic leukaemia.
    Van Der Meeren S, van der Werff ten Bosch J, Jochmans K .
    Br J Haematol. 2013;160(2):122. .

    2012

    • Dll1/Notch activation contributes to bortezomib resistance by upregulating CYP1A1 in multiple myeloma.
      Xu D, Hu J, De Bruyne E, Menu E, Schots H, Vanderkerken K, Van Valckenborgh E. .
      Biochem Biophys Res Commun. 2012; 428(4):518-24. .

    • Multiple myeloma induces the immunosuppressive capacity of distinct myeloid-derived suppressor cell subpopulations in the bone marrow.
      Van Valckenborgh E, Schouppe E, Movahedi K, De Bruyne E, Menu E, De Baetselier P, Vanderkerken K, Van Ginderachter J. .
      Leukemia 2012; 26(11): 2424-8. .

    • Expansion of polyfunctional HIV-specific T cells upon stimulation with mRNA electroporated dendritic cells in the presence of immunomodulatory drugs.
      De Keersmaecker B, Allard S, Lacor P, Schots R, Thielemans K, Aerts J .
      J Virol. 2012; 86(17):9351-60. .

    • Reference values for new red blood cell and platelet parameters on the Abbott Diagnostics Cell-Dyn Sapphire.
      Costa O, Van Moer G, Jochmans K, Jonckheer J, Damiaens S, De Waele M .
      Clin Chem Lab Med. 2012;50(5):967-9. .

    • Sorafenib has potent anti-tumor activity in multiple myeloma in vitro, ex vivo and in vivo, in the 5T33MM mouse model.
      Kharaziha P, De Raeve H, Fristedt C, Li Q, Gruber A, Johnsson P, Kokaraki G, Panzar M, Laane E, Österborg A, Zhivotovsky B, Jernberg-Wiklund H, Grandér D, Celsing F, Björkholm M, Vanderkerken K, Panaretakis T. .
      Cancer Res. 2012;72(20):5348-62. .

    • Soluble rank ligand produced by myeloma cells causes generalised bone loss in multiple myeloma.
      Buckle CH, De Leenheer E, Lawson MA, Yong K, Rabin N, Perry M, Vanderkerken K, Croucher P.I. .
      Plos One, 2012;7(8):e41127. .

    • Impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients is associated with a blockade in the deactivation of the Notch signaling pathway
      Xu S, Evans HR, Buckle CH, De Veirman K, Hu J, Xu D, Menu E, De Becker A, Vande Broek I, Leleu X, Van Camp B, Croucher PI, Vanderkerken K, Van Riet I. .
      Leukemia. 2012; 26(12): 2546-9. .

    • Identification of two de novo mutations responsible for type I antithrombin deficiency.
      Orlando C, Lissens W, Hasaerts D, Jochmans K .
      Thromb. Haemost., 2012, 107(1): 187-9. .

    • Acute stroke management in patients taking dabigatran
      Brouns R, Van Hooff R-J, De Smedt A, Moens M, De Raedt S, Uyttenboogaart M, Luijckx GJ, Jochmans K, De Keyser J .
      CNS Neuroscience & Therapeutics 2012; 18(8): 616-22. .

    • Carfilzomib: a novel treatment in relapsed and refractory multiple myeloma.
      Fostier K, De Becker A, Schots R. .
      Onco Targets Ther. 2012;5:237-44. .

    • In vitro expanded bone marrow-derived murine (C57Bl/KaLwRij) mesenchymal stem cells can acquire CD34 expression and induce sarcoma formation in vivo
      Xu S, De Becker A, De Raeve H, Van Camp B, Vanderkerken K, Van Riet I .
      Biochemical and Biophysical Research Communications, 2012;424(3):391-7 .

    • In young children, persistent wheezing is associated with bronchial bacterial infection: a retrospective analysis.
      De Schutter I, Dreesman A, Soetens O, De Waele M, Crockaert F, Verhaegen J, Pierard D, Malfroot A. .
      BMC Pediatr. 2012;12(1):83. .

    • Immunomodulatory effect of NSAID in geriatric patients with acute infection: effects of piroxicam on chemokine/cytokine secretion patterns and levels of heat shock proteins. A double-blind randomized controlled trial. (ISRCTN58517443).
      Beyer I, Njemini R, Bautmans I, Demanet C, Mets T .
      Cell Stress Chaperones, 2012; 17(2): 255-65. .

    • Diagnostic potential of CD34+ cell antigen expression in myelodysplastic syndromes.
      De Smet D, Trullemans F, Jochmans K, Renmans W, Smet L, Heylen O, Bael AM, Schots R, Leus B, De Waele M. .
      Am J Clin Pathol. 2012;138(5):732-43. .

    • Proinflammatory characteristics of SMAC/DIABLO-induced cell death in antitumor therapy
      Emeagi P, Van Lint S, Goyvaerts C, Maenhout S, Cauwels A, Mcneish IA, Bos T, Heirman C, Thielemans K, Aerts J, Breckpot K .
      Cancer Research, 2012; 72(6): 1342-52. .

    • Tumor-initiating capacity of CD138- and CD138+ tumor cells in the 5T33 multiple myeloma model.
      Van Valckenborgh E, Matsui W, Agarwal P, Lub S, Xu D, De Bruyne E, Menu E, Empsen C, Van Grunsven L, Agarwal J, Wang Q, Jernberg-Wiklund H, Vanderkerken K .
      Leukemia 2012; 26(6):1436-9 .

    • Hypoxia promotes dissemination of multiple myeloma through acquisition of endothelial to mesenchymal transition-like features.
      Azab AK, Hu J, Quang P, Azab F, Pitsillides C, Awwad R, Thompson B, Maiso P, Sun JD, Hart C, Roccaro AM, Sacco A, Ngo Hai T, Lin C, Kung AL, Carrasco RD, Vanderkerken K, Ghobrial IM .
      Blood 2012;119(24):5782-94. .

    • Continuous lenalidomide treatment for newly diagnosed multiple myeloma.
      Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, Gisslinger H, Wiktor-Jedrzejczak W, Zodelava M, Weisel K, Cascavilla N, Iosava G, Cavo M, Kloczko J, Bladé J, Beksac M, Spicka I, Plesner T, Radke J, Langer C, Ben Yehuda D, Corso A, Herbein L, Yu Z, Mei J, Jacques C, Dimopoulos MA; Augustson B, Horvath N, Joshua D, Mollee P, Prince M, Spencer A, Taylor K, Gastl AG, Greil R, Ludwig H, Iskrov I, Uss A, Fillet G, Schots R, et al. .
      New England Journal of Medicine, 2012;366(19):1759-69. .

    • The HDAC inhibitor LBH589 enhances the anti-myeloma effects of the IGF-1 RTK inhibitor picropodophyllin
      Lemaire M, Fristedt C, Agarwal P, Menu E, Van Valckenborgh E, De Bruyne E, Österborg A, Atadja P, Larsson O, Axelson M, Van Camp B, Jernberg-Wiklund H, Vanderkerken K. .
      Clinical Cancer Research, 2012; 18(8): 2230-9. .

    • Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models.
      Hu J, Van Valckenborgh E, Menu E, De Bruyne E, Vanderkerken K. .
      Dis Model Mech. 2012;5(6):763-71. .

    • Galactomannan enzymatic immunoassay cross-reactivity caused by prototheca species.
      Van Den Bossche D, De Bel A, Hendrickx M, De Becker A, Jacobs R, Naessens A, Pierard D. .
      J Clin Microbiol. 2012;50(10):3371-3. .

    • Inhibition of firefly luciferase by general anesthetics: Effect on in vitro and in vivo bioluminescence imaging.
      Keyaerts M, Remory I, Caveliers V, Breckpot K, Bos T, Poelaert J, Bossuyt A, Lahoutte T. .
      Plos One, 2012;7(1):e30061. .

    • Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls: results of a multicenter field trial.
      Samama MM, Contant G, Spiro TE, Perzborn E, Le Flem L, Guinet C, Gourmelin Y, Martinoli JL, Adcock DM, Cambus JP, Elalamy I, Gerotziafas G, Gouin-Thibault I, Harenberg J, Horellou MH, Jacquemin M, Jochmans K, et al. .
      Clin Appl Thromb Hemost. 2012;18(2):150-8. .

    • Cellular aging and senescence characteristics of human T-lymphocytes.
      Onyema O, Njemini R, Bautmans I, Renmans W, De Waele M, Mets T. .
      Biogerontology, 2012; 13: 169-81 .

    • Inflammation-related muscle weakness and fatigue in geriatric patients.
      Beyer I, Njemini R, Bautmans I, Demanet C, Bergmann P, Mets T .
      Exp Gerontol, 2012; 47 (1): 52-9 .

    • Activation of ATF4 mediates the unwanted Mcl-1accumulation by proteasome inhibition.
      Hu J, Dang N, Menu E, De Bruyne E, Xu D, Van Camp B, Van Valckenborgh E, Vanderkerken K. .
      Blood, 2012, 119( 3):826-37 .

    • Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls.
      Samama MM, Contant G, Spiro TE, Perzborn E, Guinet C, Gourmelin Y, Le Flem L, Rohde G, Martinoli JL, Rivaroxaban Anti-Factor Xa Chromogenic Assay Field Trial Laboratories: Jochmans K et al. .
      Thromb Haemost. 2012;107(2):379-87. .

    • Bone marrow derived mesenchymal stromal cells are attracted by Multiple Myeloma cell-produced chemokine CCL25 and favor myeloma cell growth in vitro and in vivo.
      Xu S, Menu E, De Becker A, Van Camp B, Vanderkerken K, Van Riet I. .
      Stem Cells 2012; 30( 2): 266-79. .

    • Dll1/Notch activation accelerates multiple myeloma disease development by promoting CD138+ MM cell proliferation.
      Xu D, Hu J, De Bruyne E, Menu E, Van Camp B, Vanderkerken K, Van Valckenborgh E. .
      Leukemia 2012;26(6):1402-5. .

     

    Back to top

  ©2004-2014 • HEIM • Vrije Universiteit Brussel • Faculteit Geneeskunde & Farmacie • Laarbeeklaan 103 • 1090 Jette • Tel.: (+32)-(0)2-477.44.06 • heim@vub.ac.be